


# PRODUCT INFORMATION



## AZD 1080

Item No. 16676

**CAS Registry No.:** 612487-72-6  
**Formal Name:** 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-1H-indole-5-carbonitrile  
**MF:** C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>  
**FW:** 334.4  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 233, 255, 302, 347, 430 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

AZD 1080 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZD 1080 in the solvent of choice, which should be purged with an inert gas. AZD 1080 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of AZD 1080 in these solvents is approximately 0.25, 30, and 25 mg/ml, respectively.

AZD 1080 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AZD 1080 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. AZD 1080 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

The two isoforms of glycogen synthase kinase 3, GSK3α and GSK3β, constitutively phosphorylate and inactivate glycogen synthase, preventing glycogen synthesis.<sup>1</sup> They also phosphorylate proteins that are relevant to Alzheimer's disease and osteogenesis.<sup>2-4</sup> AZD 1080 is a potent, brain permeable inhibitor of GSK3α and GSK3β (K<sub>i</sub>s = 6.9 and 31 nM, respectively).<sup>5,6</sup> It shows >14-fold selectivity against several kinases, receptors, enzymes, and ion channels.<sup>5</sup> AZD 1080 inhibits tau phosphorylation in cells.<sup>5</sup> It shows good bioavailability after oral administration *in vivo*, inhibiting hippocampal tau phosphorylation and reversing cognitive deficits induced by the NMDA receptor antagonist (+)-MK-801 (item No. 10009019).<sup>5</sup> In humans, oral AZD 1080 inhibits GSK3 activity in peripheral blood lymphocytes following an initial delay in response.<sup>5</sup>

### References

1. Ring, D.B., Johnson, K.W., Henriksen, E.J., *et al. Diabetes* **52**(3), 588-95 (2003).
2. Asuni, A.A., Hooper, C., Reynolds, C.H., *et al. Eur. J. Neurosci.* **24**(12), 3387-3392 (2006).
3. Phiel, C.J., Wilson, C.A., Lee, V.M., *et al. Nature* **423**(6938), 435-439 (2003).
4. Guerrero, F., Herencia, C., Almadén, Y., *et al. PLoS One* **9**(2), e89179 (2014).
5. Georgievska, B., Sandin, J., Doherty, J., *et al. J. Neurochem.* **125**(3), 446-456 (2013).
6. Eldar-Finkelman, H. and Martinez, A. *Front. Mol. Neurosci.* **4**, 1-18 (2011).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/17/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM